Orexigen Therapeutics, Inc. (OREX) Posts Q4 Loss of 9c/Share

March 8, 2012 4:01 PM EST Send to a Friend
Orexigen Therapeutics, Inc. (NASDAQ: OREX) reported Q4 EPS of ($0.09), $0.01 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $857 thousand versus the consensus estimate of $940 thousand.

For earnings history and earnings-related data on Orexigen Therapeutics, Inc. (OREX) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings

Add Your Comment